Abstract
We aim to determine the clinical usefulness of pre-operative serum vascular endothelial growth factor (VEGF) as a predictor of outcome in patients undergoing curative resection for colorectal cancer. Serum VEGF was assayed by quantitative ELISA in 81 patients prior to curative resection for node-negative (n = 53) and node-positive (n = 28) disease. Median follow-up for patients without cancer death was 27 months (range 21–37). Pre-operative serum VEGF was significantly higher in patients who went on to develop metastases than those who did not (median, 713 pg ml–1 vs. 314 pg ml–1, P < 0.0001). Using multivariate Cox regression analysis, pre-operative serum VEGF was the most important prognostic factor independent of nodal status and adjuvant chemotherapy, and was superior to nodal status in predicting outcome (P < 0.00001). At 575 pg ml–1, pre-operative serum VEGF was 64% sensitive and 89% specific in predicting the development of metastases in curative resections, with a positive predictive value of 73% and a negative predictive value of 85%. Pre-operative serum VEGF is a powerful predictor of outcome following curative surgery for colorectal cancer. These data support the measurement of pre-operative serum VEGF as a method for selecting patients who require adjuvant therapy. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
August DA, Ottow RT and Sugarbaker PH (1984 Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3(4): 303–324
Cohen AM, Tremiterra S, Candela F, Thaler HT and Sigurdson ER (1991 Prognosis of node-positive colon cancer. Cancer 67(7): 1859–1861
Deans GT, Parks TG, Rowlands BJ and Spence RA (1992 Prognostic factors in colorectal cancer. Br J Surg 79(7): 608–613
Ellis LM and Fidler IJ (1996 Angiogenesis and metastasis. Eur J Cancer 32A(14): 2451–2460
Folkman J (1990 What is the evidence that tumours are angiogenesis dependent?. J Natl Cancer Inst 82(1): 4–6
Folkman J (1994 Angiogenesis and breast cancer. J Clin Oncol 12(3): 441–443
Folkman J and Shing Y (1992 Angiogenesis. J Biol Chem 267(16): 10931–10934
Hermanek P, Wiebelt H, Staimmer D and Riedl S (1995 Prognostic factors of rectum carcinoma – experience of the German multicentre study of SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori 81(3 Suppl): 60–64
IMPACT B2 the International Multicentre Pooled Analysis of B2 Colon Cancer Trials Investigators (1999 Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17: 1356–1363
Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H and Imamura M (1998 Predictive value of vascular endothelial growth factor (VEGF) in metastases and prognosis of human colorectal cancer. Br J Cancer 78(10): 1379–1384
Kalbfleisch JD and Prentice RL (1980). Statistical Analysis of Failure Time Data, New York, Wiley
Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, Kerin MJ and Monson JR (1997 Utilisation of serum VEGF to predict curative colorectal cancer resections. GUT 39: 964 (suppl 3)
Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, Kerin MJ and Monson JR (1998 Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4(5): 1279–1285
Miller R and Siegmund D (1982 Maximally selected chi square statistics. Biometrics 38: 1011–1016
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA (1990 Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322(6): 352–358
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA (1995 Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122(5): 321–326
Olson RM, Perencevich NP, Malcolm AW, Chaffey JT and Wilson RE (1980 Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 45(12): 2969–2974
Pestana C, Reitemeier RJ, Moertel CG, Judd ES and Dockerty MB (1964 The natural history of carcinoma of the colon and rectum. Am J Surg 108: 826–829
Polk HC Jr and Spratt JS Jr. (1971 Recurrent colorectal carcinoma: detection, treatment, and other consideration. Surgery 69: 9–23
Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J and Pichlmayr R (1998 Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16(5): 1788–1794
Salven P, Teerenhovi L and Joensuu H (1997 A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood 90(8): 3167–3172
Salven P, Ruotsalainen T, Mattson K and Joensuu H (1998 High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small cell lung cancer. Int J Cancer 79(2): 144–146
Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR and Ellis LM (1997 Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132(5): 541–546
Williams NS, Jass JR and Hardcastle JD (1988 Clinicopathological assessment and staging of colorectal cancer. Br J Surgery 75(7): 649–652
Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T and Tominaga T (1996 Concentrations of vascular endothelial growth factor in sera of normal control and cancer patients. Clin Cancer Res 2(5): 821–826
Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K and Sasaki T (1999 Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5(7): 1823–1829
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Chin, KF., Greenman, J., Gardiner, E. et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 83, 1425–1431 (2000). https://doi.org/10.1054/bjoc.2000.1508
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1508
Keywords
This article is cited by
-
Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy
Pathology & Oncology Research (2020)
-
Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer
Tumor Biology (2014)
-
Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection
International Journal of Colorectal Disease (2013)
-
Potential Novel Drugs to Combine with Radiation in Rectal Cancer
Current Colorectal Cancer Reports (2012)
-
Preoperative Serum Placenta Growth Factor Level Is a Prognostic Biomarker in Colorectal Cancer
Diseases of the Colon & Rectum (2009)
